




Q1 2024 HIGHLIGHTS



David Loew
Chief Executive Officer

“An excellent first-quarter performance has laid a solid foundation for Ipsen's growth in 2024.”

TOTAL SALES



- Oncology
- Rare Disease
- Neuroscience

FY 2024 GUIDANCE¹ CONFIRMED

<p>Total-sales growth greater than 6.0% (at constant exchange rates)</p>	<p>Core operating margin greater than 30.0% of total sales</p>
---	---

GROWTH PLATFORMS



+19.3%



+29.8%



+22.2%



+2.6%

NEW MEDICINES



€26m




€12m



€7m

GEOGRAPHIC BREAKDOWN

Q1 2024 TOTAL SALES BY REGION



PIPELINE UPDATE

Regulatory approval and launch of Onivyde in the U.S. as a first-line treatment for metastatic pancreatic ductal adenocarcinoma

Two pre-clinical transactions

All growth rates are at constant exchange rates.

¹ Excludes any impact of any additional late-stage (Phase III clinical development or later) external-innovation opportunities and incorporates expectations for Somatuline of further generic lanreotide products in the U.S & E.U - expected adverse impact of ~1% from currencies on sales, based on average level of exchange rates in March 2024.

For further information on Ipsen's Q1 2024 sales update and definitions of financial indicators, please refer to the press release at:

www.ipsen.com/investors

Craig Marks

Vice President, Investor Relations
+44 7584 349 193
craig.marks@ipsen.com

Nicolas Bogler

Senior Manager, Investor Relations
+33 6 52 19 98 92
nicolas.bogler@ipsen.com

